Oxygen therapy is moving out of hospitals and into living rooms. As chronic respiratory conditions become more common and populations age, oxygen concentrators have become one of the most important devices in home respiratory care. Here is what the latest Grand View Research analysis says about where the oxygen concentrator market stands and where it is heading.

Market Size and Growth

The global oxygen concentrator market was valued at USD 5.0 billion in 2025. It is estimated at USD 5.2 billion in 2026 and is projected to reach USD 7.0 billion by 2033, a CAGR of 4.2% from 2026 to 2033.

What is driving growth

• Chronic respiratory disease. COPD, asthma, interstitial lung disease, and sleep apnea often require long-term oxygen therapy. Roughly 200 million people live with COPD worldwide.
• Ageing populations and home healthcare. Patients and providers increasingly prefer in-home care, which has pushed demand for reliable, easy-to-use devices.
• Reimbursement support. Favorable coverage policies in markets such as the U.S., UK, and France improve device access.
• Product innovation. Lighter devices, better batteries, and smart features keep arriving. In April 2026, Oxymed launched India's first home concentrator that adjusts oxygen flow automatically based on the patient's SpO₂ levels.

What is holding it back

• High upfront costs. New portable units start at around USD 2,000, which limits adoption in price-sensitive markets.
• Product recalls. Overheating, fire risk, battery faults, and calibration errors have led to recalls, including a Class I recall of a Jiangsu Jumao X-Care model. These raise compliance costs and can erode trust among patients and providers.

Have questions about the data or need market insights tailored to your business? Speak to Analyst

Regional Outlook

• North America: The region leads with a 35.4% revenue share in 2025, and the U.S. is its largest market. High rates of COPD, asthma, and sleep apnea, supportive reimbursement, and the presence of leading manufacturers all contribute.
• Europe: Regulation and connectivity shape the market. EU MDR certification has raised the bar for device safety, and IoT-enabled remote monitoring and predictive maintenance are gaining traction. Germany is a major market, driven by its older population and demand for home-based care.
• Asia Pacific: The region is expected to grow significantly through 2033. The WHO projects that the share of people aged 60 and above will rise from 12.2% in 2024 to 22.9% by 2050. Japanese firms such as Teijin and Daikin are building portable concentrators for home care, while China and India are scaling local production and affordable products.
• Latin America: The region offers untapped potential, particularly Brazil, where companies like CAIRE and GCE are expanding their presence.
• Middle East & Africa: Growth is supported by government healthcare investment, especially in the UAE, and by international programs that expand oxygen access in underserved regions.

Industry Leaders

The market is fragmented, with large global manufacturers competing alongside many regional specialists. Innovation, partnerships, and regulatory scrutiny are all high.

Established players

• Respironics (a subsidiary of Koninklijke Philips N.V.), which stopped selling its portable concentrators in January 2024
• GF Health Products, Inc.
• Nidek Medical Products, Inc.
• CAIRE Inc. (acquired by Niterra Co., Ltd., formerly NGK Spark Plug Co., Ltd.)
• DeVilbiss Healthcare (a subsidiary of Drive Medical)
• GCE Group
• Inogen, Inc.
• Teijin Limited
• BPL Medical Technologies

Emerging players

• MedaCure Inc.
• O2 Concepts
• React Health
• Compass Health Brands
• Belluscura
• Hoyo Scitech Co., Ltd.
• XNUO International Group (USA) Holding
• Besco Medical Limited
• Oxymed India
• Kalstein France
• Foshan Keyhub Electronic Industries Co., Ltd.

Recent moves

• January 2026: Oxymed launched the Oxymed Cure, a 5 LPM unit priced about 15% below its flagship Mini.
• June 2025: Inogen launched the Voxi 5 stationary concentrator, extending its portfolio beyond portables.
• January 2025: CAIRE launched the IntenOxy 5 stationary concentrator in the U.S. and Puerto Rico.
• February 2023: React Health acquired Invacare's respiratory line.

Want to see the full report structure, data points, and forecasts? Download Free Sample

Comparative Analysis

By product, technology, and application

Product: fixed vs. portable. Fixed concentrators led in 2025 with a 51.9% revenue share. They deliver higher oxygen output and reliable continuous therapy, and they cost less than portable models, which makes them the default for severe COPD and long-term home use. Portable concentrators are the fastest-growing product segment, thanks to their light weight, mobility, and battery-powered freedom.

Technology: continuous flow vs. pulse flow. Continuous flow led with a 55.8% share. It provides uninterrupted oxygen delivery regardless of the patient's breathing cycle, which is essential for severe respiratory conditions. Pulse flow is expected to grow fastest. It delivers oxygen in bursts timed to inhalation, which saves battery, keeps devices light, and suits patients with active lifestyles.

Application: home care vs. non-homecare. Home care dominated with a 62.6% share, driven by ageing populations, wider insurance coverage, and a preference for in-home therapy. Non-homecare, meaning hospitals and clinics, is growing at a moderate pace as respiratory-related admissions rise.

Established vs. emerging players

Established players focus on continuous innovation, acquisitions, and global distribution partnerships. Their edge is strong brand recognition, deep relationships with hospitals and home care providers, broad portfolios, and strong R&D. The trade-offs are higher prices and slower responses to niche opportunities.

Emerging players compete on cost-effective products and targeted expansion into high-growth regions. They are agile, develop products quickly, and price competitively in cost-sensitive markets. Their limits are a smaller global footprint, lower brand recognition, and fewer resources for large-scale R&D and expansion.

The pattern: fixed, continuous-flow devices dominate today on cost and reliability, while portable, pulse-flow devices are where innovation and growth are concentrating. Established players hold the trust of providers, and emerging players are competing on price and agility in high-growth regions.

Final Takeaway

With steady 4.2% growth ahead, the oxygen concentrator market rewards companies that combine safety and quality with portability, connectivity, and affordability. Strong demand from home healthcare and ageing populations suggests the next decade will favor those that can scale across both mature and emerging regions.

Explore Our Dedicated Business Service: Grand View Signal - Commodity Price Intelligence
Signal delivers monthly price assessments, historical benchmarks, forecast models, and risk analytics across metals, energy, chemicals, plastics, and more, helping you move from reactive buying to proactive sourcing.